Cirujano General

Contents by Year, Volume and Issue

Table of Contents

General Information

Instructions for Authors

Message to Editor

Editorial Board

>Journals >Cirujano General >Year 2017, Issue 3

Chapa-Azuela Ó, Roca-Vásquez C, Flores-Rangel GA, Botello-Hernández Z, Fuentes-Reyes R
Pancreatic insulinomas. Six-year experience in the Hepatopancreatobiliary Surgery Clinic of the General Hospital of Mexico
Cir Gen 2017; 39 (3)

Language: Español
References: 24
Page: 139-146
PDF: 4. Kb.

Full text


Background: Pancreatic insulinomas belong to a heterogeneous group of cancers known as neuroendocrine tumors. Their incidence is approximately 1.8 to five cases/million inhabitants; they represent between one and 2% of all pancreatic neoplasms. They can take a benign or malignant course, although insulinoma is the histological type associated with the best prognosis, with up to a 97% survival at five years for benign tumors and 30% for malignant tumors. Material and methods: Retrospective, observational, descriptive, longitudinal study in which we analyzed the records of all patients diagnosed with pancreatic insulinoma over a period of six years, with an average follow-up of 32 months. Results: A total of seven cases were found, of which 100% were benign and functional. All patients were treated surgically with curative intent, either with enucleation or resection, without presenting intraoperative complications. No patient showed clinical, serological or imagenologic data of recurrence. Conclusions: Insulinomas are tumors that occur with low frequency, they are usually functional and associated with a good prognosis.

Key words: Tumors, neuroendocrine, pancreas, insulinoma.


  1. Medrano-Guzmán R. Tumores neuroendocrinos gastroenteropancreáticos. GAMO. 2011; 10 Supl 2: 17-24.

  2. Neuroendocrine Tumors. NCCN Clinical Practice Guidelines in Oncology. Versión 2. 2016. Disponible en: https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf

  3. Halfdanarson TR, Rabe KG, Rubin J, Petersen GM. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol. 2008; 19: 1727-1733.

  4. Yao JC, Eisner MP, Leary C, Dagohoy C, Phan A, Rashid A, et al. Population-based study of islet cell carcinoma. Ann Surg Oncol. 2007; 14: 3492-3500.

  5. Moore FD, Scoinski MA, Joste NE. Endocrine tumors and malignancies. In: Skarin A, editor. Atlas of diagnostic oncology. 3rd ed. Philadelphia: Elsevier Science Limited; 2003.

  6. Modlin IM, Kidd M, Pfragner R, Eick GN, Champaneria MC. The functional characterization of normal and neoplastic human enterochromaffin cells. J Clin Endocrinol Metab. 2006; 91: 2340-2348.

  7. Klimstra DS, Arnold R, Capella C, Hruban RH, Kloppel G, Komminoth P, et al. Neuroendocrine neoplasms of the pancreas. In: Bosman FT, Carneiro F, Hruban RH, Theise N, eds. WHO classification of tumors of the digestive system. Lyon: WHO Press; 2010.

  8. Vargas-Martínez CC, Castaño-Llano R. Tumores neuroendocrinos gastroenteropancreáticos. Rev Col Gastroenterol. 2010; 25: 165-176.

  9. Zúñiga-Monge D. Tumores neuroendocrinos gastrointestinales. Med Leg Costa Rica. 2013; 30: 89-98.

  10. Cryer PE, Axelrod L, Grossman AB, Heller SR, Montori VM, Seaquist ER, et al. Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2009; 94: 709-728.

  11. James PD, Tsolakis AV, Zhang M, Belletrutti PJ, Mohamed R, Roberts DJ, et al. Incremental benefit of preoperative EUS for the detection of pancreatic neuroendocrine tumors: a meta-analysis. Gastrointest Endosc. 2015; 81: 848-856.

  12. Doppman JL, Chang R, Fraker DL, Norton JA, Alexander HR, Miller DL, et al. Localization of insulinomas to regions of the pancreas by intra-arterial stimulation with calcium. Ann Intern Med. 1995; 123: 269-273.

  13. Klöppel G, Couvelard A, Perren A, Komminoth P, McNicol AM, Nilsson O, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology. 2009; 90: 162-166.

  14. Bernini GP, Moretti A, Ferdeghini M, Ricci S, Letizia C, D’Erasmo E, et al. A new human chromogranin ‘A’ immunoradiometric assay for the diagnosis of neuroendocrine tumours. Br J Cancer. 2001; 84: 636-642.

  15. Campana D, Nori F, Piscitelli L, Morselli-Labate AM, Pezzilli R, Corinaldesi R, et al. Chromogranin A: is it a useful marker of neuroendocrine tumors? J Clin Oncol. 2007; 25: 1967-1973.

  16. Ter-Minassian M, Chan JA, Hooshmand SM, Brais LK, Daskalova A, Heafield R, et al. Clinical presentation, recurrence, and survival in patients with neuroendocrine tumors: results from a prospective institutional database. Endocr Relat Cancer. 2013; 20: 187-196.

  17. Yao JC, Pavel M, Phan AT, Kulke MH, Hoosen S, St Peter J, et al. Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus. J Clin Endocrinol Metab. 2011; 96: 3741-3749.

  18. Alexakis N, Neoptolemos JP. Pancreatic neuroendocrine tumours. Best Pract Res Clin Gastroenterol. 2008; 22: 183-205.

  19. Lee LC, Grant CS, Salomao DR, Fletcher JG, Takahashi N, Fidler JL, et al. Small, nonfunctioning, asymptomatic pancreatic neuroendocrine tumors (PNETs): role for nonoperative management. Surgery. 2012; 152: 965-974.

  20. Regenet N, Carrere N, Boulanger G, de Calan L, Humeau M, Arnault V, et al. Is the 2-cm size cutoff relevant for small nonfunctioning pancreatic neuroendocrine tumors: A French multicenter study. Surgery. 2016; 159: 901-907.

  21. Lesurtel M, Nagorney DM, Mazzaferro V, Jensen RT, Poston GJ. When should a liver resection be performed in patients with liver metastases from neuroendocrine tumours? A systematic review with practice recommendations. HPB (Oxford). 2015; 17: 17-22.

  22. Bonaccorsi-Riani E, Apestegui C, Jouret-Mourin A, Sempoux C, Goffette P, Ciccarelli O, et al. Liver transplantation and neuroendocrine tumors: lessons from a single centre experience and from the literature review. Transpl Int. 2010; 23: 668-678.

  23. Basturk O, Yang Z, Tang LH, Hruban RH, Adsay V, McCall CM, et al. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms. Am J Surg Pathol. 2015; 39: 683-690.

  24. Strosberg JR, Cheema A, Weber JM, Ghayouri M, Han G, Hodul PJ, et al. Relapse-free survival in patients with nonmetastatic, surgically resected pancreatic neuroendocrine tumors: an analysis of the AJCC and ENETS staging classifications. Ann Surg. 2012; 256: 321-325.

>Journals >Cirujano General >Year 2017, Issue 3

· Journal Index 
· Links 

Copyright 2019